Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025

Oct 16, 2015, 09:00 ET from Visiongain

LONDON, October 16, 2015 /PRNewswire/ --

Kidney Cancer Therapies - Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities
Are you interested in the future of renal cancer treatments? Our new study forecasts those pharmaceutical revenues. There you find outlooks for sales growth in that industry. You also explore trends, results, treatments, R&D and opportunities, seeing commercial prospects.

Visiongain's report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and sales are possible for those cancer treatments.

Read on, then, to explore renal cancer therapy and see what future revenues that expanding pharma market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions
With our new study you explore prospects for companies developing, producing and marketing drugs for treating cancer of the human kidneys. See present trends and future possibilities.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing prospects. Also get 51 tables, 38 charts and two interviews with companies.

So avoid missing out on original data and discussions to help your work.

R&D and opportunities for sales growth - explore trends and forecasts, staying ahead
Our study's purpose is to help your research, analyses and decisions on those renal therapies, also benefiting your authority and reputation for insight.

The future looks promising for pharma companies treating those cancers. Discover the progress and gains possible there, avoiding struggles to find business information you need. See, from 2015, how patients, healthcare providers and companies can benefit.

Visiongain's analysis shows how the industry for renal cancer treatments evolves. New products enter that market and novel drug candidates reach late-stage clinical trials. Discover what future revenues are possible in that expanding pharma sector.

Although no single study covers everything, the following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for treating kidney cancer
Discover in our new report forecasted world revenue to 2025 for those anticancer medicines - existing, emerging and expected drugs.

You also gain individual revenue predictions to 2025 for five submarkets at world level. See what is possible for these therapeutic classes:
• Angiogenesis inhibitors
• mTOR inhibitors
• Monoclonal antibodies (mAbs)
• Immunotherapies
• Generics and other products.
Where lie the best sales potentials? With our analysis you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and prospects.
See how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a growing incidence of renal cancer, the demand for better treatments will continue to bolster that industry and market.
You also find sales predictions by product, exploring how they can succeed.

Predictions of leading products' sales - what is possible for those cancer-treating drugs?
How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of these eight brands:
• Sutent (sunitinib)
• Nexavar (sorafenib)
• Votrient (pazopanib)
• Inlyta (axitinib)
• Afinitor (everolimus)
• Torisel (temsirolimus)
• Avastin (bevacizumab)
• Proleukin (aldesleukin).
There you find how high sales can go, finding medicines and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.
Discover what the future holds. Our work also shows you geographical predictions, by country.

National markets - what outlooks for kidney cancer drug revenues?
Advances in the biopharma industry and market expand the use of drugs to treat renal cancer in developed and developing countries. Our work shows you individual revenue forecasts to 2025 for 11 national markets:
United States (US)
Japan
Germany, France, the United Kingdom (UK), Italy and Spain (EU5 group)
Brazil, Russia, India and China (BRIC countries).
That way, you assess countries with highest revenues and potential growth. Explore outlooks for treating that disease, including patients' and healthcare providers' needs.
You also examine developments leading to novel treatments.

R&D for those cancer therapies - developmental trends, innovations and progress
In our study you investigate that oncology - research and development on kidney cancer. You examine technological advances, seeing clinical progress and finding what it means.
Discussions appear for 21 drug candidates in the pipeline, including these agents:
• Lenvima (lenvatinib, Eisai)
• Opdivo (nivolumab, Bristol-Myers Squibb)
• Keytruda (pembrolizumab, Merck)
• Cometriq (cabozantinib, Exelixis)
• Tivantinib (ARQ197, ArQule/Daiichi Sankyo)
• IMA901 (Immatics Biotechnologies/Roche)
• Atezolizumab (MPDL3280A/Roche).
In particular, checkpoint inhibitors can bring a new era for immunotherapy and make a difference in long-term treatment success for renal cancer patients.
R&D for treating renal cancer holds strength, variety and promise. That work gains momentum from rising disease prevalence and other forces making treatments for those kidney disorders more prominent in healthcare.

Events and changes affecting companies treating kidney cancer - see what the future holds
Explore other issues, too, including these forces shaping that industry and market:
• Rising prevalence of cancers
• Effect of treatment cost on sales expansion
• Patent expiries approaching - the threat of generics for novel drug producers
• Combination medicines and targeted therapies
• Regulatory affairs - outlook for drug development and approval.
You also gain SWOT analysis, assessing what drives and restrains that pharma market.
See, then, what is possible for big pharma companies and specialists in biological drugs and related biotechnologies.

Leading companies and overall 2019 market value - what revenues are possible?
Our work predicts the world market for kidney cancer-treating drugs will reach $5.6bn in 2019. That industry will achieve revenue expansion from 2015 to 2025. With our analysis you discover how high sales can go, seeing what is possible for those drug producers.
 
That way you assess what companies hold most potential. For those therapies, explore pharmaceutical developers, producers and marketers, including these firms:
• Pfizer
• Novartis
• Roche
• Bayer Healthcare
• Bristol-Myers Squibb
• Exelixis
• Cerulean Pharma
• Merck & Co.

You also see interviews with WILEX and TVAX Biomedical. Discover what the future holds for organisations treating those renal disorders, finding what participants say and do.

7 ways Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025 helps you 

Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:
• Revenues for kidney cancer treatments to 2025 - assess that overall world market's potential, seeing scope for investments, developments and marketing
• Submarket revenues to 2025 covering 5 therapeutic categories - explore segments, seeing their sales outlooks from 2015
• Leading products' sales to 2025 - discover predicted revenues of 8 brands, seeing how well those medicines can compete and succeed
• National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
• R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinions - examine participants in that rising market, and gain two interviews, helping you stay ahead and benefit your influence
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.

Gain predictions for treating kidney cancer, getting information to help you stay ahead
With our independent analyses you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how you could save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study. Our investigation shows data, trends, opportunities and forecasts for that expanding drugs market. So avoid missing out - please get our new report here now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1514/Renal-Cancer-Treatment-Industry-Analysis-R-D-Trends-and-World-Market-Forecasts-2015-2025

Companies Listed
American Cancer Society
Amgen
Argos Therapeutics
ArQule
ASCO (American Society of Clinical Oncology)
Astellas
AstraZeneca
Aveo Pharmaceuticals
Bayer Healthcare
Brazilian Unified Health System (SUS, Sistema Único de Saúde)
Bristol-Myers Squibb
Cancer Research UK
Celldex Therapeutics
Cerulean Pharma
Cetus Corporation
Chiron Corporation
CHMP (Committee for Medicinal Products for Human Use)
Commission de la Transparence
Daiichi Sankyo Group
DMC (Data Monitoring Committee)
Eddingpharm
Eisai Co
Eisai Inc (US subsidiary of Eisa Co)
EMA (European Medicines Agency)
European Commission
European Organisation for Research and Treatment and Cancer (EORTC)
Exelixis
FDA (US Food and Drug Administration)
French National Authority for Health
GSK
Immatics Biotechnologies
Kyowa Hakko Kirin
Lpath
Medarex
Merck & Co.
MHLW (Ministry of Health, Labour, and Welfare)
Mylan
National Cancer Institute
Nestlé Health Sciences
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
Novartis
ONO Pharmaceuticals
Onyx Pharmaceuticals (owned by Amgen)
Pfizer
Pharmstandard
Prometheus Laboratories
Roche
Syndax Pharmaceuticals
Tracon Pharma
TVAX Biomedical
United Nations
WILEX AG
Wyeth

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

SOURCE Visiongain